Treatments
A prostate cancer diagnosis can be overwhelming, but advancements in treatment have given patients more options—and more hope—than ever before. Today, prostate cancer therapies range from watchful waiting to highly specialized targeted treatments that go straight to the cancer while sparing healthy tissue.
Whether you’re newly diagnosed or exploring next steps in treatment, understanding your options is a powerful first step.
Conventional Treatment Options
Depending on the stage and aggressiveness of the cancer, traditional prostate cancer treatments may include:
Active Surveillance – For slow-growing cancers, careful monitoring without immediate treatment may be recommended.
Surgery – A prostatectomy may be performed to remove the entire prostate gland.
Radiation Therapy – High-energy rays or particles are used to destroy cancer cells, often combined with hormone therapy.
Hormone Therapy – Reduces or blocks the body’s production of testosterone, which fuels the growth of prostate cancer cells.
Chemotherapy – Used for cancers that have spread or no longer respond to hormone therapy.
While these options can be highly effective, they may also impact surrounding tissues or produce significant side effects.
The Rise of Radioligand Therapy
For men with metastatic castration-resistant prostate cancer (mCRPC)—a form of prostate cancer that has spread and no longer responds to hormone therapy—Radioligand Therapy is offering a new frontier in care.
This innovative approach uses radioactive molecules that seek out cancer cells and deliver a precise dose of radiation directly to them, minimizing damage to healthy tissue.
Targeted Radiopharmaceuticals: Pluvicto & Xofigo
For men with advanced or metastatic castration-resistant prostate cancer (mCRPC), two FDA-approved therapies—Pluvicto and Xofigo—are redefining what prostate cancer care can look like.
These radiopharmaceuticals are part of a new class of Radioligand Therapy, which delivers a precise dose of radiation directly to cancer cells with minimal impact on surrounding tissues.
Pluvicto (Lutetium-177) targets PSMA receptors, proteins highly expressed on prostate cancer cells. Once bound, it delivers Lutetium-177, a radioactive particle, directly to the cancer, helping to slow progression and improve survival with fewer systemic side effects.
Xofigo (Radium-223) mimics calcium and naturally targets in on areas of bone metastasis. It delivers alpha-particle radiation to cancer that has spread to the bones—relieving pain, reducing complications, and improving quality of life.
To learn more about Pluvicto and Xofigo visit their websites:
